Reported effects of psychedelic use on those with low well-being given various emotional states and social contexts
Natasha L. Mason, Patrick C. Dolder, Kim P. C. Kuypers
Drug Science, Policy and Law 2020 DOI: 10.1177/2050324519900068 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Cross-sectional survey Peer reviewed |
|---|---|
| Sample size | 1,967 |
| Population | Online respondents who use psychedelics |
| Topics | LSD MDMA Psilocybin |
| Keywords | Mood Neuroticism Hallucinogen Clinical psychology Personality |
| Citations | 15 |
| Key findings | Individuals with low well-being and higher neuroticism scores are more likely to report positive mood changes after using LSD, psilocybin, or MDMA than those with normal well-being. |
Abstract
Background: It has been suggested that the outcome of the psychedelic experience is dependent on set and setting. While scientific research into the therapeutic potential of psychedelics is growing, it is clear that in clinical populations an optimal set and setting will not always be attainable. It was aimed to assess under which emotional and environmental circumstances psychedelic users use psychedelics, and the outcome of use given clinical characteristics, defined as low well-being and higher rates of neuroticism.
Methods: Online respondents (N = 1967) provided information about their psychedelic use, environment they consume the substance in (setting), and mood state pre/post-substance (set). Based on subjective mental well-being, respondents were separated into two groups, those with low (N = 643), and those with normal well-being (N = 1324). Personality traits, with a particular focus on neuroticism, were also assessed.
Results: Findings showed that psychedelics such as lysergic acid diethylamide and psilocybin were most commonly used at home and methylenedioxymethamphetamine (MDMA) in a party/festival setting. In most instances, all substances were used when individuals were in a positive mood, and this remained in general positive, or, when not initially positive, shifted to positive, after use. Individuals with low well-being were more likely to experience a positive mood change after use of lysergic acid diethylamide, psilocybin or MDMA than individuals with normal well-being. Furthermore, as neuroticism scores increased, so did likelihood of positive mood change, as well as likelihood of experiencing negative side effects.
Conclusion: It is demonstrated that psychedelics are used in varying emotional states and environmental settings. Importantly in the light of future clinical studies with patients, individuals with low psychological well-being and higher scores of neuroticism report consuming such substances with positive outcomes.
Comparable studies
Other cross-sectional and survey studies on LSD, most cited first.
Citations in the library
Cited by 11
- The clinical pharmacology and potential therapeutic applications of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) Journal of Neurochemistry February 12, 2022
- Persisting Effects of Ayahuasca on Empathy, Creative Thinking, Decentering, Personality, and Well-Being Frontiers in Pharmacology October 1, 2021
- Sustained, Multifaceted Improvements in Mental Well-Being Following Psychedelic Experiences in a Prospective Opportunity Sample Frontiers in Psychiatry June 29, 2021
- The potential synergistic effects between psychedelic administration and nature contact for the improvement of mental health. Health Psychology Open July 1, 2020
- Investigation of self-treatment with lysergic acid diethylamide and psilocybin mushrooms: Findings from the Global Drug Survey 2020 Journal of Psychopharmacology March 6, 2023
and 6 more in the library
Cites 29
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Psychopharmacology July 7, 2006
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry May 17, 2016
- Safety and Efficacy of Lysergic Acid Diethylamide-Assisted Psychotherapy for Anxiety Associated With Life-threatening Diseases The Journal of Nervous and Mental Disease March 4, 2014
and 24 more in the library